106 citations
,
June 2005 in “Journal of Investigative Dermatology” This study defines classification criteria for hair follicle dystrophy using a mouse model of chemotherapy-induced alopecia, providing tools for standardized hair damage assessment.
80 citations
,
January 1995 in “The Nephron journals/Nephron journals” This study concluded that a sequential regimen of prednisolone and cyclophosphamide, followed by low-dose prednisolone and azathioprine, achieved favorable results in most patients with diffuse proliferative and/or membranous lupus nephritis without significant toxicities.
39 citations
,
November 2015 in “Pediatric Nephrology” In this study, rituximab treatment for children with steroid-dependent nephrotic syndrome was associated with a longer remission time and fewer side effects compared to cyclophosphamide.
39 citations
,
October 2014 in “Schweizerische medizinische Wochenschrift” This study found that while cyclophosphamide remains effective for severe autoimmune conditions, it is associated with gastrointestinal side effects, infections, some cases of irreversible amenorrhoea, and a higher risk of malignancies, emphasizing the need for long-term monitoring.
36 citations
,
April 1994 in “PubMed” This study introduces a mouse model of cyclophosphamide-induced alopecia, which effectively replicates human chemotherapy-induced hair loss and can be pharmacologically manipulated to study hair regrowth patterns.